Korean Drug Co Ltd

Korean Drug Co Ltd maintains a strong liquidity position, with a current ratio of 8.33, indicating that the company holds significantly more current assets than current liabilities. The company's cash and equivalents amount to KRW 4,847,182,630, and its operating cash flow is KRW 13,109,993,640, suggesting robust cash generation from operations. The debt-to-equity ratio is 0.0, reflecting a conservative capital structure with no long-term debt obligations. In terms of profitability, the company's return on equity (ROE) is 7.84%, and its return on assets (ROA) is 6.9%. These figures are in line with the industry's preferred metrics for profitability and asset efficiency. The company's net income of KRW 6,512,029,110 and operating income of KRW 6,913,176,840 indicate a healthy margin profile, supported by a gross profit of KRW 26,600,531,410. The company's revenue is concentrated in its domestic market, with no disclosed international segments. According to the financial snapshot, the company operates as a single business unit, and there is no information on geographic revenue distribution. This suggests a high degree of revenue concentration in the Korean market, which could expose the company to regional economic and regulatory risks. The company's growth trajectory is supported by its strong cash flow and profitability. While there is no explicit guidance on future revenue growth, the company's operating cash flow and free cash flow of KRW 6,270,756,990 indicate a capacity for reinvestment or shareholder returns. The capital expenditure of KRW -475,045,360 suggests a reduction in capital spending, which may reflect a focus on optimizing existing operations rather than expansion. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's conservative capital structure, with no long-term debt and a high current ratio, supports this low-risk profile. Additionally, the absence of dilution risk suggests that the company is not currently issuing new shares to raise capital, which could be a positive sign for existing shareholders. Recent events, including filings and transcripts, do not indicate any material changes in the company's operations or financial position. The company's financial statements and disclosures are consistent with a stable and well-managed business. There are no notable events or announcements that would suggest a significant shift in the company's strategy or performance.